<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85828">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02107950</url>
  </required_header>
  <id_info>
    <org_study_id>SOV02</org_study_id>
    <secondary_id>2013-001323-38</secondary_id>
    <nct_id>NCT02107950</nct_id>
  </id_info>
  <brief_title>Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma</brief_title>
  <official_title>A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial DCVAC/OvCa Added to Standard Chemotherapy in Women With Relapsed Platinum Sensitive Epithelial Ovarian Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sotio a.s.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sotio a.s.</source>
  <oversight_info>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether DCVAC/OvCa added to Standard of Care
      chemotherapy (carboplatin and gemcitabine as second line chemotherapy) may result in
      prolongation of progression free survival (PFS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Determine median progression free survival</measure>
    <time_frame>72 Week</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (all causes)</measure>
    <time_frame>56, 64, 72 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>8, 16, 24, 32, 40, 48, 56. 64. 72 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological Progression Free Interval</measure>
    <time_frame>6, 12, 18, 24, 36, 42, 48, 56, 64, 72 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological Response</measure>
    <time_frame>24, 48, 72 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>8, 16, 24, 32, 40, 48, 56. 64. 72 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <condition>Ovarian Cancer (OvCa)</condition>
  <condition>Ovarian Epithelial Cancer</condition>
  <arm_group>
    <arm_group_label>DCVAC/OvCa in parallel with chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with DCVAC/OvCa and Standard of Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care carboplatin and gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCVAC/OvCa in parallel with chemotherapy</intervention_name>
    <description>DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine</description>
    <arm_group_label>DCVAC/OvCa in parallel with chemotherapy</arm_group_label>
    <other_name>DCVAC/OvCa</other_name>
    <other_name>carboplatin and gemcitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Carboplatin and Gemcitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females 18 years old and older

          -  Patients with histologically confirmed,  International Federation of Gynecology and
             Obstetrics (FIGO) stage III epithelial ovarian, primary peritoneal or fallopian tube
             carcinoma (serous, endometrioid or mucinous), who had complete remission after first
             line platinum (Pt)-based chemotherapy and are selected to receive second line
             Standard of Care chemotherapy

          -  Radiologically confirmed relapse after &gt;6 months of remission (Platinum-sensitive
             patients), found up to 4 weeks prior study entry.

          -  The patient must have at least one measureable target lesion as defined by the
             Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria to be eligible for
             enrolment in the study

        Exclusion Criteria:

          -  FIGO I,II,IV epithelial ovarian cancer

          -  FIGO III clear cells epithelial ovarian cancer

          -  Non-epithelial ovarian cancer

          -  Borderline tumors (tumors of low malignant potential)

          -  Prior or current systemic anti-cancer therapy for ovarian cancer [for example
             chemotherapy, monoclonal antibody therapy , tyrosine kinase inhibitor therapy,
             vascular endothelial growth factor (VEGF) therapy or hormonal therapy] except first
             line Platinum-based chemotherapy (with or without bevacizumab)

          -  Previous radiotherapy to the abdomen and pelvis

          -  Malignancy other than epithelial ovarian cancer, except those that have been in
             clinical remission (CR) for a minimum of 3 years, and except carcinoma in-situ of the
             cervix or non-melanoma skin carcinomas
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Richard Kapsa</last_name>
    <phone>: (+420) 2241 74448</phone>
    <email>kapsa.@sotio.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <zip>755 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cologne</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <zip>91 054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <zip>041 03</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Gliwice</city>
        <zip>45-101</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian</keyword>
  <keyword>Platinum Sensitive</keyword>
  <keyword>Epithelial</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
